421 related articles for article (PubMed ID: 25952648)
1. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
[TBL] [Abstract][Full Text] [Related]
3. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
4. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
5. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
[TBL] [Abstract][Full Text] [Related]
6. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
7. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
8. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF).
Hendrix MJ; Seftor EA; Seftor RE; Kirschmann DA; Gardner LM; Boldt HC; Meyer M; Pe'er J; Folberg R
Am J Pathol; 1998 Apr; 152(4):855-63. PubMed ID: 9546344
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
[TBL] [Abstract][Full Text] [Related]
10. Decitabine limits escape from MEK inhibition in uveal melanoma.
Gonçalves J; Emmons MF; Faião-Flores F; Aplin AE; Harbour JW; Licht JD; Wink MR; Smalley KSM
Pigment Cell Melanoma Res; 2020 May; 33(3):507-514. PubMed ID: 31758842
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
12. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.
Capparelli C; Rosenbaum S; Berger AC; Aplin AE
J Biol Chem; 2015 Oct; 290(40):24267-77. PubMed ID: 26269601
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
Ambrosini G; Khanin R; Carvajal RD; Schwartz GK
Mol Cancer Ther; 2014 Aug; 13(8):2073-80. PubMed ID: 24899684
[TBL] [Abstract][Full Text] [Related]
16. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
[TBL] [Abstract][Full Text] [Related]
18. PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma.
Wang Z; He C; Liu L; Ma N; Chen X; Zheng D; Qiu GH
Neoplasma; 2017; 64(3):377-388. PubMed ID: 28253717
[TBL] [Abstract][Full Text] [Related]
19. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.
Capparelli C; Rosenbaum S; Berman-Booty LD; Salhi A; Gaborit N; Zhan T; Chervoneva I; Roszik J; Woodman SE; Davies MA; Setiady YY; Osman I; Yarden Y; Aplin AE
Cancer Res; 2015 Sep; 75(17):3554-67. PubMed ID: 26206558
[TBL] [Abstract][Full Text] [Related]
20. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
